Relative resistance of a macroprolactinoma to bromocriptine therapy during pregnancy

Gynecological Endocrinology

Volumn 10, Issue 2, 1996, Pages 91-94

  Shanis, B S ^a,b   Check, J H ^a  

^a UNIVERSITY OF MEDICINE AND DENTISTRY OF NEW JERSEY   (United States)

^b NONE   (United States)

Author keywords

Macroprolactinoma; Parlodel; Pregnancy

Indexed keywords

BROMOCRIPTINE; DOPAMINE RECEPTOR STIMULATING AGENT;

ADULT; ARTICLE; CASE REPORT; FEMALE; HUMAN; HYPOPHYSIS ADENOMA; PREGNANCY; PRIORITY JOURNAL; PROLACTINOMA; TRANSSPHENOIDAL SURGERY; TUMOR VOLUME;

EID: 0029967860     PISSN: 09513590     EISSN: None     Source Type: Journal    
DOI: 10.3109/09513599609097897     Document Type: Article

References (24)

1. Gemzell, C. and Wang, C. F. (1979). Outcome of pregnancy in women with pituitary adenoma. Fertil. Steril., 31, 363-72
2. Shupnik, M. A., Baxter, L. A., French, L. R. and Gorski, J. (1979). In vivo effects of estrogen on ovine pituitaries: prolactin and growth hormone biosynthesis and messenger ribonucleic acid translation. Endocrinology, 104, 729-35
3. Rasmussen, A. T. (1934). The weight of the principal components of normal hypophysis cerebri of adult human female. Am. J. Anat., 55, 253-75
4. Scheithauer, B., Santo, T., Kovacs, K., Young, W., Ryan, N. and Randall, R. (1990). The pituitary gland in pregnancy: a clinicopathologic and immunohistochemical study of 69 cases. Mayo Clin. Proc., 65, 461-74
5. Molitch, M. E. (1985). Pregnancy and the hyperprolactinemic woman. N. Engl. J. Med., 312, 1364-70
6. Abu-Fadil, S., DeVane, G., Siler, T. and Yen, S. S. C. (1976). Effects of oral contraceptive steroids on pituitary prolactin secretion. Contraception, 13, 79-85
7. Corenblum, B. (1993). The safety of physiological estrogen plus progestin replacement therapy and with oral contraceptive therapy in women with pathological hyperprolactinemia. Fertil. Steril., 59, 671-3
8. Woodhouse, N. J. Y., Niles, N., McDonald, D. and McCorkell, S. (1986). Prolactin levels in pregnancy: comparison of normal subjects with patients having micro- or macroadenomas after early bromocriptine withdrawal. Horm. Res., 21, 1-9
9. Radwanska, E., McGarrigle, H. H. G., Little, V., Lawrence, D., Sarris, S. and Swyer, G. I. M. (1979). Induction of ovulation in women with hyperprolactinemic amenorrhea using clomiphene and human chorionic gonadotropin or bromocriptine. Fertil. Steril., 32, 187-92
10. Swyer, G. I. M., Little, V. and Harries, B. J. (1971). Visual disturbance in pregnancy after induction of ovulation. Br. Med. J., 4, 90-1
11. Jewelewicz, R., Zimmermane, A. and Carmel, P. W. (1977). Conservative management of a pituitary tumor during pregnancy following induction of ovulation with gonadotropins. Fertil. Steril., 28, 35-40
12. Ruiz-Velasco, V. and Tolis, G. (1984). Pregnancy in hyperprolactinemic women. Fertil. Steril., 41, 793-805
13. Ahmed, M., Al-Dossary, E. and Woodhouse, N. J. Y. (1992). Macroprolactinomas with suprasellar extension: effect of bromocriptine withdrawal during one or more pregnancies. Fertil. Steril., 58, 492-7
14. Crosignani, P., Ferrari, C. and Mattei, A. M. (1984). Visual field defects and reduced visual acuity during pregnancy in two patients with prolactinoma: rapid regression of symptoms under bromocriptine. Case reports. Br. J. Obstet. Gynaecol., 91, 821-3
15. Molitch, M. (1989). Management of prolactinomas. Ann. Rev. Med., 40, 225-32
16. Magyar, D. M. and Marshall, J. R. (1978). Pituitary tumors and pregnancy. Am. J. Obstet. Gynecol., 132, 739-51
17. Lamberts, S. W. J., Seldenrath, H. J., Kwa, H. G. and Birkenhager, J. C. (1977). Transient bitemporal hemianopsia during pregnancy after treatment of galactorrhea-amenorrhea syndrome with bromocriptine. J. Clin. Endocrinol. Metab., 44, 180-4
18. Maraschini, C., Moro, M., Masala, A., Toja, P., Alagna, S., Brunani, A., Rovasio, P. P., Ginanni, A., Lancranjan, I. and Cavagnini, F. (1991). Chronic treatment with Parlodel Lar® of patients with prolactin-secreting tumours. Different responsiveness of micro- and macroprolactinomas. Acta Endocrinol., 125, 494-501
19. Brue, T., Pellegrini, I., Priou, A., Morange, I. and Jaquet, P. (1992). Prolactinomas and resistance to dopamine agonists. Horm. Res., 38, 84-9
20. Yousem, D. M., Arrington, J. A., Zinreich, S. J., Jumar, A. and Bryan, R. N. (1989). Pituitary adenomas: possible role ot bromocriptine in intratumoral hemorrhage. Radiology, 170, 239-43
21. Verhelst, J. A., Froud, A. L., Touzel, R., Wass, J. A., Besser, G. M. and Grossman, A. B. (1991). Acute and long-term effects of once-daily oral bromocriptine and a new long-acting non-ergot dopamine agonist, quinagolide, in the treatment of hyperprolactinemia: a double-blind study. Acta Endocrinol., 125, 385-91
22. Rasmussen, C., Brownell, J. and Bergh, T. (1991). Clinical response and prolactin concentration in hyperprolactinemic women during and after treatment for 24 months with the new dopamine agonist, CV 205-502. Acta Endocrinol., 125, 170-6
23. Brue, T., Pellegrini, I., Gunz, G., Morange, I., Dewailly, D., Brownell, J., Enhalbert, A. and Jaquet, P. (1992). Effects of the dopamine agonist CV205-502 in human prolactinomas resistant to bromocriptine. J. Clin. Endocrinol. Metab., 74, 577-84
24. Pellegrini, I., Rasolonjanahary, R., Gunz, G., Bertrand, P., Delivet, S. Jedynak, C. P., Kordon, C., Peillon, F., Jaquet, P. and Enjalbert, A. (1989). Resistance to bromocriptine in prolactinomas. J. Clin. Endocrinol. Metab., 69, 500-9